^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/05/2020
Excerpt:
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
Source:
Published date:
05/21/2020
Excerpt:
Olaparib is a treatment option for patients with mCRPC and a pathogenic mutaion (germline /somatic) in a homologous recombination repair gene (BRCA1, BRCA2, ATM, BADR1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L) who have been treated with androgen-receptor therapy.
Source:
Title:
LBA8 - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Published date:
11/22/2019
Excerpt:
Cohort A included pts with alterations in BRCA1, BRCA2 or ATM; Cohort B pts with any 1 of 12 other HRR alterations (BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D or RAD54L)….In pts with mCRPC and HRR alterations with prior NHA treatment, ola improved rPFS and ORR vs pcNHA, with a favorable trend for OS despite crossover.
Trial ID:
Source:
Title:
LBA12_PR - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Published date:
09/30/2019
Excerpt:
In pts with mCRPC and HRR alterations with prior NHA treatment, ola improved rPFS and ORR vs pcNHA, with a favourable trend for OS despite crossover.
Trial ID:
Source:
Title:
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Excerpt:
...- The presence of homologous recombination deficiency defined by either; A) Inherited pathogenic variant of BRCA2, ATM, BRCA1, PALB2 by a Clinical Laboratory Improvement Act (CLIA) level germline assay or B) have evidence by somatic sequencing using a CLIA level assay of biallelic inactivation of BRCA1, BRCA2, PALB2, FANCA or biallelic inactivation or monoallelic inactivating mutation of ATM....
Trial ID:
Source:
Title:
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
Excerpt:
...one or more close blood relative with ovarian carcinoma at any age or breast cancer age 50 or younger or two relatives with breast, pancreatic or prostate cancer (Gleason 7 or higher) at any age, or patients with Ashkenazi Jewish ancestry; however, patients with previously identified genetic aberrations that are associated with homologous recombination deficiency (HRD) will be eligible even in the absence of family history (e.g....
Trial ID:
Less C2 evidence
Source:
Title:
Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
Published date:
09/01/2022
Excerpt:
A partial response, good response, and high response were achieved in 89% (23/26), 59% (15/26), and 15% (4/26) of HRRmt group patients, respectively….Olaparib was effective in mCRPC patients with HRR deficiency.
DOI:
https://doi.org/10.1016/j.prnil.2022.04.005
Title:
A transcriptomic model for homologous recombination deficiency in prostate cancer
Published date:
07/05/2021
Excerpt:
In a prospective trial of mCRPC treated with olaparib (n = 10), all three men with HRD-P+ experienced prolonged (>330 days) PSA progression-free survival.
DOI:
10.1038/s41391-021-00416-2
